Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9789—Magnoliopsida [dicotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/004—Aftersun preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/06—Preparations for care of the skin for countering cellulitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/74—Biological properties of particular ingredients
  • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Definitions

• the present invention relates to the field of cosmetics and dermatology, in particular the novel cosmetic and/or dermatological use of an extract of the Nephelium lappaceum plant for increasing the firmness and/or the elasticity of the skin and/or mucous membranes.
• Collagen is a major constituent protein of the extracellular matrix (ECM) present in large amounts in vertebrate tissues. It is part of a superfamily of 29 distinct members, including fibrillar collagens. Type I collagen is the best known example thereof, but type V collagen is also a fibrillar collagen. Type V collagen is found in the same tissues as type I collagen, and is known to aid the assembly of heterogeneous fibers composed of these 2 types of collagen. They thus ensure the maintaining of the structures and gives the tissues their mechanical strength. Thus, at the level of the dermis, it contributes to the firmness of these tissues, and therefore to the firmness of the skin.
• ECM extracellular matrix
• the collagen expression decreases, inducing a relaxation of these tissues, and therefore a loss of tone and of firmness of the skin.
• Various extrinsic factors are also responsible for loss of firmness of the skin and/or mucous membranes, including aggressive environmental agents such as UV radiation, pollution or tobacco.
• Other intrinsic factors may also be responsible for disorganization of collagen fibers and a decrease in firmness, in particular hormonal variations, and changes in tension in the skin and/or mucous membranes (rapid weight gain or loss).
• Fibrillin-1 is, for its part, also a protein synthesized by fibroblasts, which is a constituent of the ECM in the dermis. It participates in the formation of elastic fibers consisting of elastin.
• this protein decreases during aging of the skin and/or other intrinsic factors, in particular hormonal factors, and extrinsic factors, in particular environmental factors, inducing a relaxation of elastic tissues.
• LOX-L Lysyl oxidase-like
• This enzyme allows the crosslinking of tropoelastin, which is then deposited at the microfibrils. Like collagen and fibrillin-1, its expression will decrease over time in the skin and mucous membranes.
• CYR61 Cysteine rich angiogenic inducer 61
• fibulin-5 which is a constituent of elastic fibers or else emilin-1, which is a glycoprotein of the ECM associated with elastic fibers.
• emilin-1 which is a glycoprotein of the ECM associated with elastic fibers. The formation and correct arrangement of the elastic fibers will depend on the level of expression of the proteins mentioned above.
• an extract of the Nephelium lappaceum plant has the property of increasing the firmness of the skin and/or mucous membranes, in particular by increasing type I and/or type V collagen gene and/or protein expression, in the skin and mucous membranes, but also of increasing the elasticity of the skin and/or mucous membranes, in particular by increasing fibrillin-1, LOX-L, fibulin-5 and emilin-1 gene and/or protein expression.
• the extract according to the invention is an extract of the N. lappaceum plant.
• This tree also known as rambutan, is found in southeast Asia, in particular in Malaysia and Indonesia. It is a tree 10 to 20 meters high, producing a large amount of fruit.
• This edible fruit is known for its organoleptic properties; it contains high amounts of sugars, vitamin C and iron. Decoctions of roots or dried leaves have also been used to combat fever.
• the plant from which the extract according to the invention is prepared originates from Vietnam.
• the extract according to the invention has the advantage of being effective on several types of collagens: type I and type V collagen.
• the extract therefore makes it possible to increase the firmness of the skin and/or mucous membranes by increasing type I collagen gene and/or protein expression, while in addition increasing the expression of other ECM components such as type V collagen or decreasing CYR61 expression.
• Yet another advantage of the extract according to the invention is that it makes it possible to increase the elasticity of the skin and/or mucous membranes by increasing the gene and/or protein expression of fibrillin-1 but also of LOX-L, fibulin-5 and emilin-1. This extract therefore makes it possible to target several types of ECM proteins, by making a complete cosmetic and/or dermatological ingredient.
• the extract according to the invention also has the advantage of being an ingredient that can be easily formulated and that can easily be manufactured on an industrial scale. It is a topically acceptable active ingredient for the skin and mucous membranes, which does not present a risk of allergy.
• the ingredient that is active on firmness is a pepper extract comprising capsaicin and no activity on firmness, in particular chosen from firmness, anti-cellulite activity and slimming activity, is associated with the N. lappaceum extract.
• Application KR20060007083 describes a cosmetic composition comprising an N. lappaceum extract, said composition being used as a skin-whitening agent.
• Extracts of the plant prepared by extraction in various solvents including ethanol, have been described for their free-radical scavenger activity in application WO 2008/066370.
• application JP2002145730 discloses several effects, including a moisturizing and antioxidant effect, of the seeds of the N. lappaceum plant.
• application KR20090056521 describes an extract of N. lappaceum and lychee ( Litchi chinensis ) in a cosmetic composition for the skin, having an anti-wrinkle effect and making it possible to inhibit collagen degradation by metalloproteinases (MMPs), in particular MMP-1s.
• MMPs metalloproteinases
• no effect of increasing type I or V collagen protein and/or gene expression using an N. lappaceum extract, in particular using a leaf extract is described in this prior art.
• it describes an effect of inhibiting proteinases responsible for collagen degradation, but not an increase in type I or type V collagen expression in particular.
• the invention relates to the cosmetic use of an N. lappaceum extract for increasing the firmness of the skin and/or mucous membranes.
• the invention relates to the cosmetic use of an N. lappaceum extract for increasing the elasticity of the skin and/or mucous membranes.
• an N. lappaceum extract for increasing the elasticity of the skin and/or mucous membranes.
• Firmness is closely related to the density of the extracellular matrix, in particular but not exclusively to collagen expression.
• Elasticity is related to the formation and assembly of elastic fibers, in which the fibrillin-1, LOX-L, fibulin-5 and emilin-1 proteins participate.
• the term “cosmetic use” is intended to mean nontherapeutic use, that is to say intended to be applied to all or part of a healthy, non-pathological, area of skin or mucous membrane.
• the expression “area of healthy skin and/or healthy mucous membrane” is intended to mean an area of the skin and/or mucous membrane to which the extract according to the invention is applied and which is referred to as “non-pathological” by a dermatologist, that is to say which does not have an infection, scar, skin disease or disorder such as candidiasis, impetigo, psoriasis, eczema, acne or dermatitis, or wounds or injuries and/or other dermatoses.
• the extract according to the invention may be applied to all or part of the skin of the body and/or the face where the increase in firmness and/or elasticity is desired, preferentially the legs, thighs, arms, stomach, bust, neck, all or part of the face, preferentially the cheeks, forehead, chin, lips, area around the lips, area around the eyes, the “T” zone of the face.
• the skin includes the scalp.
• the term “collagen” is intended to mean type I, III, IV, V, VI, VII, XII, XIII, XIV, XVI, XVII, XVIII, XXIV and/or XXIX collagen present in the skin and/or mucous membranes. Preferentially according to the invention, it is type I and/or V collagen, even more preferentially type I collagen.
• fibrillin is, moreover, intended to mean fibrillin-1, fibrillin-2 and/or fibrillin-3, preferentially fibrillin-1 present in the skin and/or mucous membranes.
• the N. lappaceum extract according to the invention is a topically acceptable ingredient.
• topically acceptable is intended to mean an ingredient suitable for topical application, which is non-toxic, non-irritating to the skin and/or mucous membranes, which does not induce an allergic response, and which is not chemically unstable.
• the extract according to the present invention may be used orally or topically.
• topically is intended to mean the direct local application and/or spraying of the ingredient onto the surface of the skin and/or mucous membranes.
• mucous membrane is intended to mean the ocular mucous membrane, the vaginal mucous membrane, the urogenital mucous membrane, the anal mucous membrane, the nasal mucous membrane and/or the oral, labial and/or gingival mucous membrane; preferentially, the labial and/or oral mucous membranes.
• the term “increase the firmness of the skin and/or mucous membranes” is intended to mean an increase in firmness of the skin and/or mucous membranes of at least 1%, preferentially of at least 3%, more advantageously of at least 5% in the presence of an N. lappaceum extract according to the invention.
• it is an increase measured in vivo, preferentially on the skin of the human face.
• this increase in the firmness of the skin of the human face is measured after application of a cream comprising an extract of N. lappaceum leaves, preferentially present in an amount of 0.1% by weight relative to the total weight of the cream.
• the leaf extract will be present in an amount of 2% by weight relative to the total weight of the cream. In this case, it will be an extract prepared in water in subcritical conditions under the conditions described in example 1e).
• the cream is applied to a half of the face of a population of 30 women aged 55 to 65 years, and the measurement of the increase in firmness is carried out after 28 and 56 days of daily application of said cream, in comparison with the application under the same conditions of a placebo cream that does not comprise the extract of N. lappaceum leaves.
• the in vivo measurement of the firmness may be carried out according to the conventional methods known to those skilled in the art, in particular by measuring with a cutometer, a TonodermTM, a DynaSKIN® associated with a demaTOP or by means of a device named SkinFibroMeter (Delfin).
• the firmness is evaluated by measuring the distribution of the volumes of the skin subjected to pressure deformation of the SkinFibroMeter, making it possible to evaluate the biomechanical properties of the skin.
• the term “increasing the elasticity” of the skin and/or mucous membranes is also intended to mean an increase in the elasticity measured in vivo of at least 2%, advantageously of at least 4%, and more advantageously of at least 6% in the presence of the extract according to the invention, relative to the elasticity detected in the absence of the extract.
• this measurement is carried out on the skin of the human face.
• the increase in the elasticity of the skin of the human face is measured in the presence of a cream comprising an extract of N. lappaceum leaves, advantageously present in an amount of 1% by weight relative to the total weight of the cream.
• the leaf extract will be present in an amount of 2% by weight relative to the total weight of the cream. In this case, it will be an extract prepared in water in subcritical conditions under the conditions described in example 1e).
• the cream is applied to a half of the face of a population of 30 women aged 55 to 65 years, and the measurement of the elasticity is carried out after 28 and 56 days of daily application of said cream, in comparison with the application under the same conditions of a placebo cream that does not comprise the extract of N. lappaceum leaves.
• the measurement of the elasticity may be carried out using a ballistometer, a corneometer or a cutometer. In one advantageous embodiment, it will be measured by cutometry, a technique for measuring the mechanical strain of the skin subjected to suction.
• the term “decreasing the wrinkles” is intended to mean a reduction of at least 0.5%, preferentially of at least 1%, more preferentially of at least 2% of fine wrinkles in the presence of the extract according to the invention with respect to the level of fine wrinkles measured in the absence of the extract.
• this measurement is carried out on the skin of the human face.
• the decrease in the fine wrinkles of the skin of the human face is measured in the presence of a cream comprising an extract of N. lappaceum leaves, advantageously present in an amount of 1% by weight relative to the total weight of the cream.
• the leaf extract will be present in an amount of 2% by weight relative to the total weight of the cream. In this case, it will be an extract prepared in water in subcritical conditions under the conditions described in example 1e).
• the cream is applied to a half of the face of a population of 30 women aged 55 to 65 years, and the measurement of the fine wrinkles is carried out after 28 and 56 days of daily application of said cream, in comparison with the application under the same conditions of a placebo cream that does not comprise the extract of N. lappaceum leaves.
• the N. lappaceum extract is not combined with any extract of the L. chinensis plant.
• the extract according to the invention is preferentially not combined with an extract of L. chinensis fruit.
• the extract according to the invention is preferentially not combined with capsaicin (CAS number 404-86-4, molar mass 305.418 g/mol) or any plant extract comprising it.
• the extract according to the invention is not combined with a fruit extract of any plant species of the Capsicum genus comprising capsaicin.
• An object of the present invention is therefore the cosmetic use of an N. lappaceum extract for increasing the firmness and/or elasticity of the skin and/or mucous membranes, by increasing type I collagen, type V collagen, emilin-1, fibulin-5 and fibrillin, preferentially fibrillin-1, and/or LOX-L gene and/or protein expression, and/or by decreasing CYR61 expression.
• a subject of the present invention is therefore the cosmetic use of an N. lappaceum extract for increasing the firmness of the skin and/or mucous membranes, by increasing type I and/or type V collagen gene and/or protein expression and/or decreasing CYR61 expression.
• Another particular subject of the present invention is the cosmetic use of an N. lappaceum extract for increasing the elasticity of the skin and/or mucous membranes, by increasing emilin-1, fibulin-5, fibrillin, preferentially fibrillin-1, and/or LOX-L gene and/or protein expression.
• gene increase is intended to mean an increase in the mRNAs encoding the protein of interest.
• the expression “increasing collagen gene and/or protein expression” is intended to mean an increase in collagen protein and/or gene expression of at least 4%, preferentially of at least 20%, even more preferentially of at least 50%, advantageously of at least 100%, and very advantageously of at least 400%, in the presence of the N. lappaceum extract according to the invention, with respect to the collagen protein and/or gene expression detected in the absence of the extract.
• the collagen expression is the protein expression of type I and/or type V collagen, more preferentially of type I collagen.
• said expression is measured in human fibroblasts described as normal, that is to say non-pathological, more preferentially in the presence of an N. lappaceum extract according to the invention, advantageously in the presence of extract 1a) or extract 1e).
• the type I and/or type V collagen protein expression is measured by immunohistochemical technique using an anti-collagen antibody as described under the conditions of example 2.
• an extract of N. lappaceum leaves is used to increase the firmness of the skin and/or mucous membranes by increasing type I and/or type V, preferentially type I, collagen gene and/or protein expression, preferentially protein expression.
• an extract of N. lappaceum leaves is used to increase the firmness of the skin and/or mucous membranes by decreasing CYR61 gene and/or protein expression, preferentially protein expression.
• the expression “decreasing CYR61 gene and/or protein expression” is intended to mean a decrease in gene and/or protein expression of at least 4%, preferentially of at least 15%, more preferentially of at least 30% in the presence of the N. lappaceum extract according to the invention, with respect to the level of CYR61 protein and/or gene expression detected in the absence of the extract.
• the decrease is a decrease in CYR61 protein expression, advantageously measured in normal, i.e. non-pathological, human fibroblasts, more preferentially measured in the presence of an N. lappaceum extract according to the invention, very advantageously in the presence of extract 1a) or 1e), under the conditions described in example 5.
• the expression “increasing fibrillin gene and/or protein expression” is intended to mean increasing fibrillin protein and/or gene expression by at least 30%, preferentially by at least 50%, more preferentially by at least 100%, advantageously by at least 150% and very advantageously by at least 200% in the presence of the N.
• lappaceum extract according to the invention with respect to the level of fibrillin protein and/or gene expression detected in the absence of the extract.
• it is a question of increasing fibrillin-1 protein expression, advantageously measured in normal, i.e. non-pathological, human fibroblasts, more preferentially measured in the presence of an N. lappaceum extract, advantageously in the presence of extract 1a) or extract 1e), under the conditions described in example 4.
• the N. lappaceum extract is used for increasing the elasticity of the skin and/or mucous membranes, by increasing fibrillin expression, advantageously fibrillin-1 expression.
• the N. lappaceum extract is used for increasing the elasticity of the skin and/or mucous membranes by increasing LOX-L gene and/or protein expression.
• the expression “increasing LOX-L gene and/or protein expression” is intended to mean an increase of at least 2%, preferentially of at least 5%, more preferentially of at least 10% and very preferentially of at least 15% of the LOX-L gene and/or protein expression in the presence of the N. lappaceum extract according to the invention with respect to the level of LOX-L protein and/or gene expression detected in the absence of the extract.
• the increase is an increase in LOX-L protein expression, advantageously measured in normal, i.e. non-pathological, human fibroblasts, more preferentially measured in the presence of an N. lappaceum extract according to the invention, very advantageously in the presence of extract 1a) or 1e).
• the extract increases the elasticity of the skin and/or mucous membranes by increasing fibulin-5 gene and/or protein expression.
• the expression “increasing fibulin-5 gene and/or protein expression” is intended to mean an increase of at least 2%, preferentially of at least 5%, more preferentially of at least 10% and very preferentially of at least 15% of fibulin-5 gene and/or protein expression in the presence of the N. lappaceum extract according to the invention, with respect to the level of fibulin-5 protein and/or gene expression detected in the absence of the extract.
• the increase is an increase in fibulin-5 protein expression, advantageously measured in normal, i.e. non-pathological, human fibroblasts, more preferentially measured in the presence of an N. lappaceum extract according to the invention, very advantageously in the presence of extract 1a) or 1e).
• the extract increases the elasticity of the skin and/or mucous membranes by increasing emilin-1 gene and/or protein expression.
• the expression “increasing emilin-1 gene and/or protein expression” is intended to mean an increase in emilin-1 protein and/or gene expression of at least 2%, preferentially of at least 5%, more preferentially of at least 10% and very preferentially of at least 15% in the presence of the N. lappaceum extract according to the invention with respect to the level of emilin-1 protein and/or gene expression detected in the absence of the extract.
• the increase is an increase in emilin-1 protein expression, advantageously measured in normal, i.e. non-pathological, human fibroblasts, more preferentially measured in the presence of an N. lappaceum extract according to the invention, very advantageously in the presence of extract 1a) or 1e).
• a subject of the present invention is therefore the cosmetic use of an N. lappaceum extract for increasing the elasticity of the skin and/or mucous membranes, by increasing fibrillin-1, LOX-L, fibulin-5 and/or emilin-1 gene and/or protein expression.
• an extract of leaves and/or branches and/or bark and/or stem and/or seeds, preferentially leaves, of N. lappaceum is used for increasing fibrillin-1, LOX-L, fibulin-5 and/or emilin-1 gene and/or protein expression, preferentially fibrillin-1 gene and/or protein expression, more preferentially fibrillin-1 protein expression, to increase the elasticity of the skin and/or mucous membranes.
• the extract may be all or part of the N. lappaceum plant chosen from the bark, leaves, branches, stem, whole fruit, fruit pulp, seeds, pericarp, root.
• the extract is a leaf and/or seed and/or pulp and/or branch extract. More preferentially, the extract is a leaf extract.
• the whole plant or the part of the plant in question is preferentially dried and/or milled before extraction.
• the term “pulp” is intended to mean the fruit without the pericarp and without the seed.
• the term “pericarp” is intended to mean the envelope of the fruit, also referred to as the shell.
• the term “bark” is also intended to mean the bark of the tree and/or of the branches.
• the term “branch” is intended to mean the wood and the bark.
• seed is intended to mean the seed without the pulp.
• the extract can be obtained by various extraction methods known to those skilled in the art, chosen from maceration, hot decoction, by milling including ultrasonic milling, using a mixer, or else the extract can be obtained by extraction in water under subcritical conditions.
• the extraction is carried out by maceration.
• the extraction is carried out in water under subcritical conditions.
• the extraction is not carried out under supercritical conditions (CO 2 ).
• the extraction may be carried out at a temperature ranging from 4° C. to 300° C., including ambient temperature, that is to say a temperature of 20° C.
• the extraction will be carried out at a temperature of from 60° C. to 90° C., preferentially from 70° C. to 85° C., more preferentially at a temperature of 80° C.
• the extraction will be carried out at a temperature of from 4° C. to 25° C., more preferentially from 4° C. to 20° C., more advantageously at ambient temperature, that is to say at 20° C.
• the extraction will be carried out in water under subcritical conditions, at a temperature ranging from 100° C. to 374° C., advantageously from 120° C. to 250° C., more advantageously at 120° C.
• the extraction can be carried out at a single given temperature or at successive increasing temperatures.
• the extraction will be carried out sequentially at three increasing temperatures of 120° C., 140° C. and 160° C.
• extraction under “subcritical conditions” is intended to mean extraction in the presence of water, under conditions of temperature greater than 100° C. and pressure less than 221 bar, such that the water remains in the liquid state but has a viscosity and a surface tension lower than that of water at ambient temperature, increasing its dielectric constant.
• the extraction pressure will between 150 bar and 250 bar, preferentially between 200 and 221 bar, advantageously in a pressure extraction autoclave.
• the extraction can be carried out for a period of from 30 minutes to 24 hours, preferentially from 30 minutes to 12 hours, more preferentially for a period of from 1 hour to 5 hours, and more advantageously for a period of from 1 hour to 2 hours. Very advantageously, the extraction will be carried out for a period of 1 hour.
• the extract according to the invention may be obtained by extraction in a solvent or solvent mixture, preferably a protic polar solvent, and advantageously in water, an alcohol, a glycol, a polyol, a water/alcohol, water/glycol or water/polyol mixture (such as water mixed with ethanol, glycerol and/or butylene glycol and/or other glycols such as xylitol and/or propanediol, etc.), from 99/1 to 1/99 (w/w), advantageously in water as sole solvent.
• the extract is a leaf extract prepared in water as sole solvent.
• extract obtained by aqueous extraction is intended to mean any extract obtained by extraction with an aqueous solution containing more than 60% by weight, advantageously at least 70% by weight, in particular at least 80% by weight, more particularly at least 90% by weight, particularly at least 95% by weight, of water relative to the total weight of the aqueous solution, even more advantageously not containing glycol and in particular not containing alcohol, more particularly only containing water.
• the extract is obtained by extraction in a mixture of propanediol and water in the respective proportion (80, 20; w/w).
• the extraction may moreover be carried out in the presence of a nonionic surfactant, preferentially chosen from lauryl glucoside sold under the name Plantacare® 1200UP by BASF or else caprylyl/capryl glucoside (Plantacare® 810 UP), preferentially caprylyl/capryl glucoside (Plantacare® 810 UP).
• the concentration by weight of the nonionic surfactant may be between 0.5% and 5%, advantageously between 0.5 and 1%, more advantageously it will be 1% by weight relative to the total weight of the extract.
• the extract can be obtained by extraction of an amount of from 0.1% to 10% by weight of fresh material or solids, preferentially solids, of at least one part of the N. lappaceum plant relative to the total weight of the solvent/plant mixture (w/w).
• the extract is obtained by extraction of an amount of from 1% to 10% by weight, advantageously from 5% to 10%, more advantageously of 10% by weight of solids of at least one part of the plant, relative to the total weight of the mixture consisting of the solvent, preferentially water, and of the plant (w/w).
• the extract will be obtained from an amount of 10% by weight of at least one part of the plant relative to the total weight of the solvent/plant mixture (w/w), then concentrated to 20%.
• the part of the plant will then be the seeds.
• the extract is obtained by maceration in water as sole solvent, of an amount of 10% by weight of dried leaves of the N. lappaceum plant relative to the total weight of leaves and water, at a temperature of 80° C., for a period of 1 hour, under the conditions described in example 1a).
• the crude extract obtained is then decanted, centrifuged and then filtered.
• the extract obtained may optionally be dried and will be in powder form.
• the extract is obtained by maceration from an amount of 5% by weight of dried leaves of the N. lappaceum plant relative to the total weight of leaves and water, at a temperature of 80° C., for a period of 1 hour, under the conditions described in example 1b).
• the crude extract obtained is then decanted, centrifuged and then filtered.
• the extract is obtained by maceration from an amount of 10% by weight of dried branch of the N. lappaceum plant relative to the total weight of branch and water, at ambient temperature, that is to say at a temperature of 20° C., for a period of 2 hours, under the conditions described in example 1c).
• the extraction is carried out in the presence of a concentration by weight of 1% of caprylyl/capryl glucoside (Plantacare® 810 UP).
• the crude extract obtained is then decanted, centrifuged and then filtered.
• the extraction is carried out by maceration from an amount of 10% by weight of dried leaves of N. lappaceum in a propanediol/water mixture (80, 20; v/v) at a temperature of 80° C. for a period of 1 hour, under the conditions described in example 1 d).
• the crude extract obtained is then decanted, centrifuged and then filtered.
• the extraction is carried out by extraction in water under subcritical conditions, of an amount of 10% by weight of dried leaves of N. lappaceum in a pressure extraction autoclave, at a temperature of 250°, under a pressure of 250 bar under the conditions described in example 1e).
• the crude extract obtained is then decanted, centrifuged and then filtered.
• the extract obtained may optionally be dried.
• the extraction will be carried out by maceration of an amount of 10% by weight of the fruit pulp relative to the total weight of pulp and water as sole solvent, at a temperature of 80° C., for a period of 1 hour, under the conditions described in example 1f).
• the extraction of pulp may be carried out starting from an amount of 10% by weight of pulp, in a propanediol/water mixture (80, 20; v/v) at a temperature of 80° C. for a period of 1 hour.
• the extraction of pulp may be carried out by extraction in water under subcritical conditions. The crude extract obtained is then decanted, centrifuged and then filtered.
• the extraction will be carried out by maceration of an amount of 10% of seeds by weight relative to the total weight of the seeds and water as sole solvent, at ambient temperature, that is to say at 20° C., for a period of 2 hours, under the conditions described in example 1g).
• the extraction of seeds may be carried out starting from an amount of 10% by weight of seeds, in a propanediol/water mixture (80, 20; v/v) at a temperature of 80° C. for a period of 1 hour.
• the extraction of seeds may be carried out by extraction in water under subcritical conditions. The crude extract obtained is then decanted, centrifuged and then filtered.
• the extract obtained and used according to the invention may then be centrifuged and/or filtered and/or distilled to recover the soluble fraction, preferentially the water-soluble fraction.
• the supernatant obtained is then filtered, advantageously at a cut-off threshold of 0.45 ⁇ m. Additional decolorizing and/or deodorizing steps can be carried out on the extract at any stage of the extraction and according to the techniques known to those skilled in the art.
• the extract may be decolorized with activated carbon.
• the extract can then be concentrated by evaporation of the solvent or dried, for example by lyophilization or by spray-drying in the presence of maltodextrins.
• the extract will then be in powder form.
• the extract obtained will be spray-dried in the presence of a concentration by weight of maltodextrins of between 20% and 90%, preferentially between 40% and 80%, more preferentially from 70% to 80% relative to the total weight of the powder obtained.
• the N. lappaceum extract obtained is sterilized.
• the extract can be used alone in the form of a cosmetic or dermatological ingredient, or in a cosmetic or dermatological composition, comprising at least one cosmetically or dermatologically acceptable excipient.
• a solvent in particular a polar solvent, such as water, an alcohol, a polyol, a glycol, such as pentylene glycol and/or butylene glycol and/or hexylene glycol and/or caprylyl glycol, or a mixture thereof, preferentially an aqueous-glycolic mixture, more preferentially containing a glycol chosen from hexylene glycol, caprylyl glycol and mixtures thereof.
• a polar solvent such as water, an alcohol, a polyol, a glycol, such as pentylene glycol and/or butylene glycol and/or hexylene glycol and/or caprylyl glycol, or a mixture thereof.
• the extract obtained is diluted and/or soluble in an aqueous solution containing hexylene glycol, in particular containing between 0.1% and 10% by weight of hexylene glycol, preferentially between 0.5% and 5% by weight of hexylene glycol, relative to the total weight of the aqueous solution.
• the extract obtained is diluted and/or soluble in an aqueous solution containing caprylyl glycol, in particular containing between 0.01% and 5% by weight of caprylyl glycol, preferentially between 0.1% and 1% by weight of caprylyl glycol, relative to the total weight of the aqueous solution.
• the aqueous solution in which the N.
• the solution in which the N. lappaceum extract is solubilized according to the invention comprises hexylene glycol, caprylyl glycol and xanthan gum.
• the extract will be solubilized in an aqueous solution comprising glycerin at a concentration by weight relative to the total weight of the cosmetic ingredient of from 50% to 85%, advantageously from 60% to 80%, more advantageously of 79%, biopropanediol at a concentration by weight relative to the total weight of the cosmetic ingredient of from 5% to 20%, advantageously of 10%, and water.
• the extract can also be present in a cosmetic composition further comprising at least one cosmetically acceptable excipient,
• Cosmetically acceptable excipient is intended to mean a cosmetic excipient or excipient non-irritating to the skin, which does not induce an allergic response and is chemically stable.
• a subject of the present invention therefore relates to the use of the extract of the N. lappaceum plant according to the invention in a cosmetic composition for increasing the firmness and/or elasticity of the skin and/or mucous membranes, by increasing type I and/or type V collagen, preferentially type I collagen, LOX-L, fibulin-5, emilin-1 and/or fibrillin, preferentially fibrillin-1, gene and/or protein expression, and/or by decreasing CYR61 expression, in the skin and/or mucous membranes.
• the cosmetic composition comprising the N. lappaceum extract according to the invention may be applied, preferentially topically, to all or part of the body and/or the face where an increase in firmness and/or elasticity is desired, preferentially the legs, thighs, arms, stomach, bust, neck, all or part of the face, preferentially the cheeks, forehead, chin, lips, area around the lips, area around the eyes, the “T” zone of the face.
• the extract is present in the cosmetic or dermatological composition at a concentration of 1 ⁇ 10 ⁇ 4 % to 10%, preferentially from 1 ⁇ 10 ⁇ 4 % to 5%, and even more preferentially from 1 ⁇ 10 ⁇ 3 % to 3% by weight, relative to the total weight of the composition.
• the excipient(s) may be chosen from surfactants and/or emulsifiers, preservatives, buffers, chelating agents, denaturing agents, opacifiers, pH adjusters, reducing agents, stabilizers, thickeners, gelling agents, film-forming polymers, fillers, mattifying agents, gloss agents, pigments, dyes, fragrances and mixtures thereof.
• CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes various cosmetic excipients suitable for use in the present invention.
• the excipient(s) are chosen from the group comprising polyglycerols, esters, cellulose polymers and derivatives, lanolin derivatives, phospholipids, lactoferrins, lactoperoxidases, saccharose-based stabilizers, vitamin E and its derivatives, xanthan gums, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiables, phytosterols, silicones, protein hydrolyzates, betaines, aminoxides, plant extracts, saccharose esters, titanium dioxides, glycines, and parabens, and more preferably from the group consisting of steareth-2, steareth-21, glycol-15 stearyl ether, cetearyl alcohol, phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylparaben, butylene glycol, caprylyl glycol, natural tocopherols, glycerin, di
• the cosmetic composition according to the invention may be chosen from an aqueous or oily solution, a cream or an aqueous gel or an oily gel, especially a shower gel, a milk, an emulsion, a microemulsion or a nanoemulsion, which is especially oil-in-water or water-in-oil or multiple or silicone-based, a mask, a serum, a lotion, a liquid soap, a dermatological bar, an ointment, a foam, a patch, an anhydrous product, which is preferably liquid, pasty or solid, for example in the form of makeup powders, a rod or a stick, in particular in the form of a lipstick.
• it is a cream or a serum.
• composition used according to the invention may also contain cosmetic active ingredients leading to a complementary or synergistic effect, such as anti-aging active agents.
• cosmetic active ingredients leading to a complementary or synergistic effect, such as anti-aging active agents.
• active agents that stimulate the synthesis of macromolecules of the dermis or prevent the degradation thereof, agents that stimulate keratinocyte proliferation, soothing agents, moisturizing agents, or else agents that act on regulating the size of pores and/or the opening thereof.
• an active agent which stimulates collagen such as retinol and/or vitamin C;
• the agents which stimulate keratinocyte proliferation comprise in particular retinoids such as retinol and esters thereof, including retinyl paimitate, and phloroglucinol.
• the agents which stimulate keratinocyte differentiation comprise, for example, minerals such as calcium and lignans such as secoisolariciresinol and also the Achillea millefollium extract sold under the name NeurobioxTM by BASF Beauty Care Solutions France.
• soothing agents preferentially of use in the composition according to the invention, mention may be made of: pentacyclic triterpenes, ursolic acid and salts thereof, oleanolic acid and salts thereof, betulinic acid and salts thereof, salicylic acid salts and in particular zinc salicylate, bisabolol, allantoin, omega-3 unsaturated oils, cortisone, hydrocortisone, indomethacin and betamethasone, anti-inflammatory active agents, and especially those described in application FR 2 847 267, in particular the Pueraria lobata root extract sold under the name Inihipase® by BASF Beauty Care Solutions France SAS, Theobroma cacao extracts.
• Cichorium intybus extract sold under the name LOX-AGETM by BASF Beauty Care Solutions France
• synthetic sarcosine sold under the name Mat-XSTM Clinical and/or an Orthosiphon stamineus extract as described in patent application WO2010/063674 in the name of BASF Beauty Care Solutions France and sold under the name MAT XSTM Bright.
• moisturizing agents preferentially of use in the composition according to the invention, mention may be made of: a combination of pullulan, of sodium hyaluronate and of sodium alginate, such as that sold by BASF Beauty Care Solutions France under the name PatcH 2 OTM.
• Another subject of the invention also relates to a cosmetic care method comprising the application, topically or orally, preferentially topically, of the extract according to the invention or of a cosmetic composition comprising it to increase the firmness and/or the elasticity of the skin and/or mucous membranes.
• the cosmetic care method according to the invention is for increasing type I and/or type V collagen, preferentially type I collagen, gene and/or protein expression, and/or decreasing CYR61 expression, in the skin and/or mucous membranes to increase the firmness of the skin and/or mucous membranes.
• Another subject of the invention relates to a cosmetic care method which comprises the topical or oral application, preferentially topical application, of the N. lappaceum extract according to the invention or of a cosmetic composition comprising it, for increasing the elasticity of the skin and/or mucous membranes, by increasing fibrillin, preferentially fibrillin-1, LOX-L, fibulin-5 and/or emilin-1, more preferentially fibrillin-1, gene and/or protein expression, and advantageously protein expression, in the skin and/or mucous membranes.
• the method comprises the topical application to all or part of the skin of the body and/or face where an increase in firmness and/or elasticity is desired, preferentially the legs, thighs, arms, stomach, bust, neck, all or part of the face, preferentially the cheeks, forehead, chin, lips, area around the lips, area around the eyes, the “T” zone of the face, of the extract according to the invention or a cosmetic composition comprising it.
• N. lappaceum extract for use thereof, topically or orally and preferentially topically, alone or in a pharmaceutical composition, preferentially a dermatological composition, comprising it, in the prevention and/or treatment of pathological conditions involving a loss of collagen, preferentially type I collagen, protein and/or gene expression and/or a pathological loss of firmness of the skin and/or mucous membranes, such as rosacea or telangiectasia.
• N. lappaceum extract for use thereof, topically or orally and preferentially topically, alone or in a pharmaceutical composition, preferentially a dermatological composition, comprising it, in the prevention and/or treatment of pathological conditions involving a loss of fibrillin, preferentially type I fibrillin, protein and/or gene expression and/or a pathological loss of elasticity of the skin and/or mucous membranes, such as solar elastosis, cutis laxa disease and/or stretch marks.
• a dermatological composition comprising it, in the prevention and/or treatment of pathological conditions involving a loss of fibrillin, preferentially type I fibrillin, protein and/or gene expression and/or a pathological loss of elasticity of the skin and/or mucous membranes, such as solar elastosis, cutis laxa disease and/or stretch marks.
• the extract is included in the dermatological or pharmaceutical composition comprising, moreover, at least one dermatologically or pharmaceutically acceptable excipient, at a concentration of from 1 ⁇ 10 ⁇ 4 % to 10%, preferentially from 1 ⁇ 10 ⁇ 4 % to 5%, and more preferentially from 1 ⁇ 10 ⁇ 3 % to 3% by weight, relative to the total weight of the composition.
• Example 1a The extract was obtained by maceration in water as sole solvent, of an amount of 10% by weight of dried leaves of the N. lappaceum plant relative to the total weight of leaves and water as sole solvent, at a temperature of 80° C., for a period of 1 hour.
• the crude extract was decanted, centrifuged and then filtered. This extract may then be subsequently dried.
• Example 1b The extract vas obtained by maceration starting from an amount of 5% by weight of leaves of the N. lappaceum plant relative to the total weight of dried leaves and water as sole solvent, at a temperature of 80° C., for a period of 1 hour.
• the crude extract was centrifuged and then filtered.
• Example 1c) The extract was obtained by maceration starting from an amount of 10% by weight of dried branches of the N. lappaceum plant relative to the total weight of branches and water as sole solvent, at ambient temperature, that is to say at a temperature of 20° C., for a period of 2 hours in the presence of a concentration by weight of 1% of caprylyl/capryl glucoside (Plantacare® 810 UP).
• the crude extract was decanted, centrifuged and then filtered.
• Example 1d The extraction was carried out by maceration starting from an amount of 10% by weight of dried leaves of N. lappaceum in a propanediol/water mixture (80, 20; w/w) at a temperature of 80° C. for a period of 1 hour.
• the crude extract was decanted, centrifuged and then filtered.
• Example 1e The extraction was carried out starting from an amount of 10% by weight of dried leaves of N. lappaceum in water under subcritical conditions, in a pressure extraction autoclave, at a temperature of 250° C., under a pressure of 250 bar. The crude extract was decanted, centrifuged and then filtered.
• Example 1f The extraction was carried out by maceration in water as sole solvent, starting from an amount of 10% by weight of fruit pulp of N. lappaceum relative to the total weight of the pulp and water, at a temperature of 80° C. for a period of 1 hour.
• the crude extract was decanted, centrifuged and then filtered.
• Example 1g The extraction was carried out by maceration in water as sole solvent of an amount of 10% of seeds by weight relative to the total weight of the seeds and water, at ambient temperature, that is to say 20° C., for a period of 2 hours.
• the crude extract was decanted, centrifuged and then filtered.
• Example 1h The extract was obtained by maceration starting from an amount of 10% by weight of dried branch of the N. lappaceum plant relative to the total weight of branch and water as sole solvent, at a temperature of 80° C., for a period of 1 hour.
• the crude extract was decanted, centrifuged and then filtered.
• Example 2 Increase in Type I Collagen Expression in the Presence of Various N. lappaceum Extracts According to the Invention
• N. lappaceum extracts increased type V collagen protein expression by at least 4% and up to at least 400% in the normal fibroblasts analyzed, demonstrating their properties of increasing the firmness of the skin and mucous membranes.
• the proteins were identified by capillary electrophoresis (ProteinSimple, USA) using an anti-fibrillin primary antibody and immunolocalized using a peroxidase-coupled conjugated secondary antibody. The results were quantified using the Compass Software (version 2.7.1 (ProteinSimple)).
• the results showed an increase of at least 30% and up to at least 200% of fibrillin-1 protein expression in the normal human fibroblasts, showing its ability to increase the elasticity of the skin and/or mucous membranes.
• the CYR61 protein of interest was detected by capillary electrophoresis (Antibody AbCam (ab24448)e diluted to 1/50) then revealed with a horseradish peroxidase-coupled secondary antibody and a chemiluminescent substrate. The chemiluminescent signal was then detected and quantified (Compass® version 23.1 (ProteinSimple®)).
• the extract of N. lappaceum leaves showed its ability to decrease CYR61 protein expression.
• the extract is therefore active on the firmness of the skin and/or mucous membranes.
• the amounts indicated are as percentage by weight relative to the total weight of the cosmetic ingredient.
• compositions below are prepared according to methods known to those skilled in the art, in particular as regards the various phases to be mixed together.
• the cosmetic ingredient is prepared according to example 6 above.
• the amounts indicated are as percentage by weight relative to the total weight of the composition.

Applications Claiming Priority (3)

Publications (2)

Family

ID=59409483

Family Applications (1)

Country Status (8)

Families Citing this family (4)

Citations (15)

Family Cites Families (6)

• 2017
  • 2017-05-05 FR FR1753987A patent/FR3065876B1/fr active Active
• 2018
  • 2018-05-03 EP EP18728212.4A patent/EP3618802A1/fr active Pending
  • 2018-05-03 WO PCT/FR2018/051095 patent/WO2018203000A1/fr active Application Filing
  • 2018-05-03 JP JP2019559749A patent/JP2020518593A/ja active Pending
  • 2018-05-03 CN CN201880029897.7A patent/CN110603031A/zh active Pending
  • 2018-05-03 BR BR112019022610-9A patent/BR112019022610B1/pt active IP Right Grant
  • 2018-05-03 KR KR1020197033804A patent/KR102588031B1/ko active IP Right Grant
  • 2018-05-03 US US16/610,942 patent/US11517520B2/en active Active
• 2022
  • 2022-12-23 JP JP2022206171A patent/JP2023052050A/ja active Pending

Patent Citations (20)

Non-Patent Citations (23)

Also Published As

Similar Documents

Legal Events